$0.25 EPS Expected for FGL Holdings (FG); Dicerna Pharmaceuticals (DRNA) Shorts Raised By 26.17%

April 17, 2018 - By Hazel Jackson

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had an increase of 26.17% in short interest. DRNA’s SI was 1.24M shares in April as released by FINRA. Its up 26.17% from 980,000 shares previously. With 593,300 avg volume, 2 days are for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Inc’s float is 10.16%. The stock increased 3.78% or $0.39 during the last trading session, reaching $10.7. About 156,471 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 274.53% since April 17, 2017 and is uptrending. It has outperformed by 262.98% the S&P500.

Analysts expect FGL Holdings (NYSE:FG) to report $0.25 EPS on May, 9 after the close.FG’s profit would be $53.59M giving it 9.97 P/E if the $0.25 EPS is correct. The stock decreased 0.50% or $0.05 during the last trading session, reaching $9.97. About 134,817 shares traded. FGL Holdings (NYSE:FG) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Investors sentiment increased to 3 in Q4 2017. Its up 2.21, from 0.79 in 2017Q3. It increased, as 6 investors sold Dicerna Pharmaceuticals, Inc. shares while 5 reduced holdings. 18 funds opened positions while 15 raised stakes. 29.10 million shares or 180.62% more from 10.37 million shares in 2017Q3 were reported. Dimensional Fund Lp accumulated 18,244 shares. Ecor1 Cap Ltd Llc accumulated 4.84 million shares. Deutsche Comml Bank Ag has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Camber Cap invested 0.44% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 806 are owned by Manufacturers Life Insurance The. Ghost Tree Ltd Liability invested in 500,000 shares or 1.06% of the stock. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 32 shares. Barclays Public Limited Company invested in 0% or 21,478 shares. California Employees Retirement Sys invested in 0% or 41,000 shares. Bridger Limited Liability Com has 905,998 shares for 0.54% of their portfolio. Emerald Mutual Fund Advisers Tru owns 570,861 shares or 0.2% of their US portfolio. Emerald Advisers Pa has 0.01% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Alpine Lc reported 11,473 shares stake. Endurant Mngmt L P holds 0.05% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 18,837 shares. 64,340 are held by Eam Investors Ltd Liability Com.

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Chardan Capital Markets with “Neutral” on Monday, August 15. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by Chardan Capital Markets on Friday, March 9. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Thursday, June 30. Stifel Nicolaus maintained it with “Buy” rating and $10.0 target in Thursday, November 2 report. The firm has “Buy” rating given on Friday, March 9 by Stifel Nicolaus. The firm has “Buy” rating given on Friday, August 11 by H.C. Wainwright. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Mkt Perform” rating by Leerink Swann on Tuesday, January 31. Stifel Nicolaus maintained the shares of DRNA in report on Wednesday, November 11 with “Buy” rating. The company was maintained on Thursday, June 30 by Chardan Capital Markets. As per Monday, February 5, the company rating was initiated by SunTrust.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $553.91 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Since December 18, 2017, it had 1 buy, and 1 insider sale for $1.98 million activity. Weissman James B sold $13,455 worth of stock. Another trade for 285,000 shares valued at $2.00 million was made by Bain Capital Life Sciences Investors – LLC on Monday, December 18.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>